Fevipiprant, a DP₂ receptor antagonist, inhibits eosinophil migration towards mast cells

Clin Exp Allergy. 2019 Feb;49(2):255-257. doi: 10.1111/cea.13304. Epub 2018 Nov 25.

Authors

Revital Shamri¹, Gerald Dubois², Veit J Erpenbeck³, David Mankuta⁴, David A Sandham^{2

5}, Francesca Levi-Schaffer¹

Affiliations

¹ The Hebrew University of Jerusalem, Jerusalem, Israel.
² Novartis Institutes for Biomedical Research Horsham, Horsham, UK.
³ Novartis Pharma AG, Basel, Switzerland.
⁴ Department of Gynecology, Hadassah Hospital, Jerusalem, Israel.
⁵ Novartis Institutes for Biomedical Research, Cambridge, MA, USA.

PMID: 30379368
DOI: 10.1111/cea.13304

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell Movement / drug effects*
Eosinophils / immunology*
Humans
Indoleacetic Acids / pharmacology*
Mast Cells / immunology*
Pyridines / pharmacology*
Receptors, Immunologic / antagonists & inhibitors*
Receptors, Immunologic / immunology
Receptors, Prostaglandin / antagonists & inhibitors*
Receptors, Prostaglandin / immunology

Substances

Indoleacetic Acids
Pyridines
Receptors, Immunologic
Receptors, Prostaglandin
fevipiprant
prostaglandin D2 receptor